Table 1.

Double-blind randomized placebo-controlled trials of addition of spironolactone or eplerenone to an ACEi-based regimen in chronic kidney disease

Study groups
Control	Experimental	Δ Proteinuria or albuminuria	Δ BP lower vs. placebo	n	Weeks
ACEi + placebo [44]	ACEi + spironolactone	−33%	Yes	21	8
ACEi + placebo [45]	ACEi + spironolactone	−32%	No	20	8
ACEi + placebo [46]	ACEi + eplerenone	−48%	Yes	268	12
ACEi + placebo [47]	ACEi + spironolactone	−40%	Yes	59	48
ACEi + placebo [48]	ACEi + spironolactone	−45%	Yes	27	12
ACEi + placebo [49]	ACEi + spironolactone	−55%	No	81	48

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; MRB, mineralocorticoid blocker.